Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp |
Therapy | CD19-PD-1/CD28-CAR T cells |
Indication/Tumor Type | B-cell lymphoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | B-cell lymphoma | sensitive | CD19-PD-1/CD28-CAR T cells | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CD19-PD-1/CD28 CAR T cell treatment induced dose-dependent cytotoxicity against a B cell lymphoma cell line with CD274 overexpression in culture, and resulted in greater inhibition of tumor growth in a cell line xenograft model compared to treatment with anti-CD19 CAR T cells alone or combined with an anti-PD-1 antibody (PMID: 33028589). | 33028589 |
PubMed Id | Reference Title | Details |
---|---|---|
(33028589) | CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. | Full reference... |